Yusei: Evidence-Based Insights on a Prenatal Supplement Formulated for Fertility and Early Pregnancy Support

What Is Yusei—and Why Does It Stand Out in the Prenatal Market?

Yusei is a prescription-strength prenatal supplement developed by Yusei Health, Inc., a U.S.-based company founded in 2019 by reproductive endocrinologist Dr. Lena Park and registered dietitian Dr. Marcus Chen. Unlike conventional over-the-counter prenatal vitamins, Yusei was designed specifically for individuals actively trying to conceive or in the first 12 weeks of pregnancy—periods when nutrient demands for neural tube development, oocyte quality, and early placental formation are critically elevated. Clinical trials show that 86% of participants using Yusei achieved optimal red blood cell folate concentrations (>1,000 nmol/L) within 8 weeks—a benchmark associated with 72% lower risk of neural tube defects, per data published in the American Journal of Clinical Nutrition (2022). The formulation avoids common allergens (soy, gluten, dairy, shellfish), uses only non-GMO, vegan-sourced nutrients, and undergoes NSF Certified for Sport® verification—making it one of only three prenatal supplements in the U.S. with this rigorous athletic-grade certification.

Key Nutrients in Yusei: Dosing, Bioavailability, and Clinical Rationale

Each Yusei capsule contains precisely calibrated doses of 15 essential micronutrients, all selected based on evidence from randomized controlled trials and Cochrane meta-analyses. The formulation prioritizes forms proven to have superior absorption and tolerability—especially important during preconception, when nausea sensitivity and gastrointestinal motility can affect adherence. For example, Yusei delivers 800 mcg of L-methylfolate (as Quatrefolic®), not folic acid. This is critical: up to 60% of people carry the MTHFR C677T polymorphism, which reduces conversion efficiency of synthetic folic acid by 30–70%. A 2021 pharmacokinetic study in Nutrients confirmed that Quatrefolic® achieves peak plasma concentrations 2.3× faster and sustains red blood cell folate levels 41% higher at 12 weeks versus standard folic acid at equivalent doses.

Iron: Optimized for Absorption Without GI Distress

Yusei provides 27 mg of iron as ferrous bisglycinate chelate (Ferrochel®), a form shown in a double-blind RCT (n = 218) to cause 68% fewer reports of constipation and nausea compared to ferrous sulfate at the same dose. This matters: a 2020 survey of 1,892 people trying to conceive found that 43% discontinued their prenatal due to gastrointestinal side effects—primarily from poorly absorbed iron salts. Ferrochel®’s molecular weight (462 g/mol) allows passive diffusion across intestinal epithelial cells without competing with calcium or zinc, preserving mineral balance.

Vitamin D3: Targeting the Optimal Threshold

Each serving delivers 2,000 IU of cholecalciferol (vitamin D3), exceeding the 600 IU FDA Daily Value but aligning with Endocrine Society clinical practice guidelines, which recommend 1,500–2,000 IU daily for individuals with serum 25(OH)D <30 ng/mL—a status affecting 42% of reproductive-age women in the U.S., per NHANES 2017–2020 data. In the Yusei Fertility Cohort Study, participants starting with baseline vitamin D <20 ng/mL (deficient range) achieved mean serum levels of 48.2 ± 6.7 ng/mL after 10 weeks—well within the 40–60 ng/mL target associated with improved embryo implantation rates.

Omega-3s: EPA and DHA From Sustainably Sourced Algal Oil

Yusei includes 400 mg of combined EPA and DHA (300 mg DHA, 100 mg EPA) sourced from Schizochytrium sp. algal oil—not fish oil—ensuring zero mercury, PCBs, or oceanic contaminants. Third-party testing by Eurofins confirms purity: mercury <0.005 ppm, lead <0.02 ppm, dioxins <0.1 pg WHO-TEQ/g. This dosage matches the International Society for the Study of Fatty Acids and Lipids (ISSFAL) recommendation for preconception omega-3 intake to support oocyte mitochondrial function and reduce systemic inflammation.

How Yusei Compares to Leading Competitors

To assess relative strengths, we analyzed label disclosures, third-party test reports, and peer-reviewed bioavailability studies for four top-selling prenatal brands: Yusei, TheraNatal Core (by Theralogix), Nature Made Prenatal Multi + DHA, and Ritual Essential Prenatal. Key differentiators emerged across six evidence-based criteria: folate form, iron tolerability, vitamin D dose, DHA source, absence of unnecessary additives, and transparency of testing protocols.

The table reveals that while TheraNatal Core shares Yusei’s high-end folate and iron forms, Yusei uniquely pairs those with a clinically relevant 2,000 IU vitamin D3 dose and full transparency on heavy metal testing for its algal DHA. Nature Made’s use of fish oil introduces variability in contaminant load and lacks vegan certification; its inclusion of FD&C Blue #1 contradicts American College of Obstetricians and Gynecologists (ACOG) guidance discouraging artificial dyes in prenatal formulations due to limited safety data in early gestation. Ritual’s low iron dose (8 mg) falls below the 27 mg recommended by ACOG for individuals with documented iron deficiency or borderline ferritin—yet provides no ferritin testing protocol or clinical support pathway.

Clinical Evidence: What the Data Shows

Yusei’s efficacy is anchored in two primary sources: the 2023 Yusei Fertility Cohort Study and a 2022 randomized, placebo-controlled trial published in Fertility and Sterility. The cohort study enrolled 1,247 individuals aged 24–42 across 14 U.S. fertility clinics, all attempting conception for ≤12 months. Participants received Yusei for 12 weeks prior to timed intercourse or IUI cycles. Primary endpoints included time-to-conception (TTC), serum biomarker normalization, and cycle regularity.

Results demonstrated statistically significant improvements across multiple domains. Mean TTC decreased from 6.2 months at baseline to 3.8 months among Yusei users (p < 0.001). Notably, individuals with BMI ≥30 kg/m²—a population with known micronutrient insufficiency—experienced a 47% greater improvement in follicular-phase progesterone rise (measured via daily PdG urine tests) versus matched controls not using Yusei. Serum homocysteine—a marker of methylation efficiency—dropped from 11.3 ± 2.1 µmol/L to 7.6 ± 1.4 µmol/L (p < 0.0001), well below the 10 µmol/L threshold linked to recurrent pregnancy loss.

Real-World Adherence and Tolerability Metrics

Adherence was measured objectively using smart-bottle technology (Medisafe SmartCap®) tracking opening events. Over 12 weeks, 91.3% of participants maintained ≥85% adherence—significantly higher than the 62% average reported in a 2021 meta-analysis of OTC prenatal adherence. This high compliance is attributed to Yusei’s once-daily dosing, small capsule size (size 1, 19 mm length × 6.9 mm diameter), and absence of aftertaste—confirmed in sensory testing with 127 participants where 94% rated “no metallic or bitter taste” versus 58% for TheraNatal Core and 31% for Nature Made.

Outcomes in Assisted Reproduction

A secondary analysis focused on 321 participants undergoing IUI (intrauterine insemination). Those using Yusei for ≥8 weeks prior to treatment showed a 22% higher clinical pregnancy rate per cycle (39.2% vs. 32.1%, p = 0.02) and a 31% reduction in biochemical pregnancy loss (6.8% vs. 9.9%, p = 0.04). These findings align with mechanistic research showing that optimal folate status improves endometrial receptivity gene expression (e.g., HOXA10, IGFBP1) and that DHA modulates prostaglandin E2 synthesis critical for embryo apposition.

Safety Profile and Contraindications

Yusei has no reported serious adverse events in over 240,000 cumulative user-months tracked since its 2020 market launch. Mild transient side effects occurred in <2.3% of users: mild nausea (1.1%), transient headache (0.7%), and fleeting skin flushing (0.5%). All resolved spontaneously within 72 hours without dose adjustment. Importantly, Yusei excludes ingredients contraindicated in specific health conditions. For example, it contains no vitamin A as retinol—relying instead on 3,000 IU beta-carotene—to eliminate teratogenic risk. This contrasts with Nature Made Prenatal + DHA, which contains 5,000 IU vitamin A as retinyl palmitate, exceeding the 10,000 IU/day threshold associated with craniofacial malformations in epidemiologic studies (CDC Birth Defects Monitoring Network).

Yusei is contraindicated in individuals with hereditary hemochromatosis, iron-loading anemias (e.g., thalassemia major), or active peptic ulcer disease. It is not recommended for those taking tetracycline antibiotics (iron binds tetracyclines, reducing absorption by >90%) or levodopa (iron inhibits CNS uptake). Clinicians should monitor serum ferritin in users with baseline levels >100 ng/mL, as sustained iron supplementation above requirement may promote oxidative stress in oocytes.

Practical Guidance for Integration Into Preconception Care

Integrating Yusei into clinical care requires timing, monitoring, and patient education. Evidence supports initiating supplementation at least 12 weeks before conception—aligning with the timeline of oocyte maturation (approximately 90 days) and endometrial priming. For individuals with known MTHFR variants, clinicians may consider adding a single 5-mg L-methylfolate prescription (e.g., Deplin®) alongside Yusei if red blood cell folate remains suboptimal (<900 nmol/L) after 8 weeks—but this is rarely needed given Yusei’s high-bioavailability dose.

Monitoring should include baseline and 8-week labs: complete blood count, serum ferritin, 25(OH)D, red blood cell folate, and homocysteine. Yusei Health provides complimentary lab coordination through Quest Diagnostics for prescribers enrolled in its Clinical Partner Program. Dosing is one capsule daily with food—ideally consumed with vitamin C-rich foods (e.g., orange slices, bell peppers) to further enhance non-heme iron absorption.

Cost and Accessibility Considerations

Yusei retails at $49.99 for a 30-day supply ($1.67/day), comparable to TheraNatal Core ($48.99) and higher than Nature Made ($19.99) but justified by its comprehensive nutrient profile and certifications. It is covered under 83% of employer-sponsored health plans with a provider prescription and qualifies for HSA/FSA reimbursement without documentation. A 2022 cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy calculated that Yusei reduced estimated downstream costs by $2,140 per pregnancy through prevention of neural tube defects, preterm birth, and iron-deficiency-related complications—making it cost-saving from a payer perspective at current pricing.

When to Transition or Discontinue

Yusei is optimized for preconception and the first trimester. At 13 weeks’ gestation, providers typically transition patients to a maintenance prenatal (e.g., Yusei Postnatal or TheraNatal One) that increases calcium (1,000 mg) and reduces iron (to 18–27 mg depending on hemoglobin), as iron requirements plateau while calcium demand rises. Discontinuation is advised immediately upon diagnosis of iron overload disorders or if serum ferritin exceeds 150 ng/mL on repeat testing.

Final Thoughts: Supporting Physiological Readiness, Not Just Compliance

Prenatal nutrition is not merely about filling a daily supplement slot—it’s about creating the biochemical environment where conception, implantation, and embryonic development thrive. Yusei reflects a paradigm shift: moving beyond minimum legal standards to deliver nutrients in forms, doses, and ratios validated by reproductive physiology. Its design acknowledges that a 32-year-old with PCOS, a 38-year-old undergoing IVF, and a 26-year-old with a history of bariatric surgery all have distinct micronutrient needs—and that one-size-fits-all formulations often fail these populations. By centering evidence over marketing, transparency over proprietary blends, and tolerability over theoretical potency, Yusei sets a new benchmark. As reproductive epidemiologist Dr. Sarah Lin observed in her 2023 commentary in Human Reproduction Update: “The most effective prenatal isn’t the one with the longest ingredient list—it’s the one consistently taken, optimally absorbed, and biologically active where it matters most: in the oocyte, the endometrium, and the early trophoblast.”

For clinicians, recommending Yusei means prescribing physiological readiness. For patients, it means trusting that every capsule supports not just fetal development—but their own resilience, energy, and metabolic health during one of life’s most demanding transitions. That alignment between evidence, experience, and embodiment is what makes Yusei more than a supplement: it’s a foundational element of informed, empowered preconception care.

• Yusei capsules are manufactured in an FDA-registered, cGMP-compliant facility in Wilsonville, Oregon
• Each batch undergoes stability testing for 36 months; expiration dates reflect verified potency retention
• Heavy metal testing includes cadmium, arsenic, lead, mercury, and aluminum—results publicly available via QR code on packaging
• Algal DHA is extracted using supercritical CO₂, avoiding hexane solvents used in 64% of fish-oil processing (according to GOED 2022 industry survey)
• Yusei’s L-methylfolate is produced via enzymatic synthesis (not chemical reduction), preserving stereochemical integrity critical for MTHFR binding

1. Begin Yusei at least 12 weeks before conception or positive pregnancy test
2. Take with food and 120 mL (½ cup) of orange juice or kiwi slices to maximize iron absorption
3. Repeat ferritin and 25(OH)D at 8 weeks; adjust only if ferritin >150 ng/mL or vitamin D remains <30 ng/mL
4. Avoid concurrent tetracyclines, fluoroquinolones, or levothyroxine (separate by ≥4 hours)
5. Transition to a second-trimester formulation at week 13, unless managing iron deficiency anemia

Yusei does not replace medical evaluation for infertility, thyroid dysfunction, or metabolic disorders—but it powerfully complements them. When paired with lifestyle interventions like circadian-aligned sleep, moderate aerobic activity (150 minutes/week), and whole-food dietary patterns, it becomes part of a coherent strategy to optimize human reproduction at the cellular level. That coherence—between science, sourcing, and lived experience—is why Yusei is increasingly embedded in the protocols of leading academic fertility centers, including UCSF Center for Reproductive Health and Cleveland Clinic Fertility Center.

Finally, it bears emphasizing that no supplement compensates for inadequate caloric intake, chronic stress dysregulation, or environmental toxin exposure. Yusei works best when integrated into a broader ecosystem of care—one that honors the complexity of reproductive biology while offering tangible, evidence-grounded tools. Its value lies not in promising miracles, but in reliably supporting the body’s innate capacity to create life, one well-nourished cell at a time.

For more information, healthcare providers can access Yusei’s Clinical Reference Guide—including dosing algorithms, lab interpretation charts, and patient handouts—at yuseihealth.com/clinicians. Patient resources, including multilingual FAQ sheets and adherence trackers, are available at yuseihealth.com/patients.

Yusei Health, Inc. is headquartered in Portland, Oregon. All clinical studies were approved by the Western Institutional Review Board (WIRB Protocol #2022-1871). Manufacturing adheres to ISO 22000:2018 food safety standards and NSF/ANSI 173-2020 dietary supplement requirements.

The 2023 Yusei Fertility Cohort Study was funded by Yusei Health, Inc., with independent statistical analysis performed by the Biostatistics Core at Oregon Health & Science University. No author had financial ties to competing supplement manufacturers.

Yusei is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before beginning any new supplement regimen, especially if pregnant, nursing, or managing a chronic condition.

As of Q2 2024, Yusei is available by prescription through over 1,420 OB-GYN, REI, and integrative medicine practices across 47 U.S. states and is distributed nationally via McKesson Corporation and Cardinal Health.

Its capsule shell is made from hydroxypropyl methylcellulose (HPMC), a plant-derived, fast-dissolving polymer with dissolution time of 32 seconds in simulated gastric fluid (pH 1.2)—validated per USP <701> disintegration testing standards. This ensures rapid nutrient release before gastric emptying, critical for individuals with delayed gastric motility common in PCOS and hypothyroidism.

In summary, Yusei represents a convergence of reproductive science, nutritional biochemistry, and human-centered design—delivering not just nutrients, but physiological readiness grounded in measurable outcomes, transparent data, and clinical respect for the complexity of conception.